NRx Pharmaceuticals and subsidiary to acquire interest in Cohen clinic, Florida

NRx Pharmaceuticals (NRXP) and its wholly-owned subsidiary HOPE Therapeutics, a multi-site clinical care delivery organization, signed a binding Letter of Intent to purchase a 49% interest in Cohen and Associates. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida. Cohen offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation as well as medication management. The potential acquisition of Cohen is subject to the execution of definitive transaction documents and standard closing requirements. Further details regarding the terms of the transaction will be disclosed at that time.